MHRA Issues Warning Over Botox Due to Hospitalization Spike

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a stark warning as it intensifies efforts to combat the illegal use and distribution of unlicensed botulinum toxin products, commonly known as Botox. This follows a concerning rise in hospital admissions believed to be linked to unregulated cosmetic procedures.

Investigations Launched Amid Surge in Botulism Cases

The MHRA’s Criminal Enforcement Unit has initiated several criminal investigations in response to 41 confirmed cases of botulism recorded between June 4 and August 6, 2025. Cases have been reported across multiple regions in England, including the North East, East Midlands, East of England, North West, and Yorkshire and Humber. Botulism, though rare, can be life-threatening. It is caused by toxins produced by the Clostridium botulinum bacteria, which attack the nervous system and can lead to paralysis.

"Botulism caused by botulinum toxin in cosmetic procedures is rare, but can be life-threatening", stated the MHRA. The agency explained that while most people recover fully with prompt medical care, untreated cases may result in paralysis spreading to the muscles responsible for breathing, which is fatal in 5% to 10% of cases.

Unregulated Procedures Raise Alarm

The MHRA has warned that some sellers and practitioners - many of whom lack adequate training - are illegally obtaining unlicensed botulinum toxin products and administering treatments in unsafe, unregulated environments. These informal settings include domestic bedrooms, kitchens, hair salons, and mobile beauty services. Social media platforms are reportedly being used to lure customers with promises of quick, inexpensive results.

According to the agency, "The Criminal Enforcement Unit has seen evidence that some sellers and practitioners - often untrained - are obtaining unlicensed botulinum toxin products illegally and offering injections in unsafe, unregulated settings."

Public Safety at Risk

The MHRA is encouraging people to remain vigilant about the risks posed by unlicensed botulinum toxin products. It advises individuals to ensure that practitioners are appropriately trained and qualified, and that the products used are licensed in the UK. "Be suspicious of unusually cheap prices, treatments offered in domestic settings, or practitioners who cannot provide proper credentials", the agency warned.

Symptoms of botulism resulting from cosmetic procedures may take up to four weeks to manifest and can include difficulty swallowing, slurred speech, and trouble breathing. Severe cases may require intensive care and mechanical ventilation. The MHRA advises anyone experiencing these symptoms after receiving botulinum toxin treatments to seek immediate medical help via NHS 111 or emergency services.

Crackdown on Illegal Imports

The MHRA’s crackdown has been bolstered by its collaboration with Border Force, resulting in the seizure of over 4,700 vials of unlicensed botulinum toxin products since May 2023. Most of these products, including brands such as Botulax, reNTox, Innotox, and Toxpia, originated from South Korea and are not authorized for sale in the UK.

Under the Human Medicines Regulations 2012, individuals caught selling or supplying unlicensed botulinum toxin products in the UK face penalties of up to two years in prison and unlimited fines.

Prioritizing Safe Practices

The MHRA emphasizes the importance of using licensed botulinum toxin products that have undergone rigorous safety testing. Legitimate treatments should only be carried out in clinical settings equipped for emergencies and prescribed specifically for individual patients.

As the MHRA continues its efforts to disrupt the illegal supply of unlicensed products, it urges the public to prioritize safety when considering cosmetic procedures. By verifying practitioner qualifications and product authenticity, individuals can help protect themselves from the serious risks associated with unsafe treatments.

Read the source